StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Alexion Pharma (ALXN): MG P3 Miss Increases Importance of ALXN-1210; PT to $160 - BMO
June 7, 2016 6:18 AM
BMO Capital analyst, Ian Somaiya, cut his price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $160 from $168 following disappointing ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst PT Change
FDA
Next Articles
Oppenheimer Cuts Price Target on Alexion Pharma (ALXN) Following Data Release
June 7, 2016 9:46 AM
Alexion (ALXN) Buy On Weakness - Piper Jaffray
June 7, 2016 9:29 AM
Alexion Pharmaceuticals (ALXN) PT Lowered to $186 at Credit Suisse
June 7, 2016 8:38 AM
Alexion Pharma (ALXN) Phase 3 REGAIN Study of Eculizumab Did Not Reach Statistical Significance
June 6, 2016 4:03 PM
Alexion Announces Topline Results from Phase 3 REGAIN Study of Eculizumab (Soliris®) in Patients with Refractory Generalized Myasthenia Gravis (gMG)
June 6, 2016 4:01 PM
